Comparative clinical study of cefcapene pivoxil and cefteram pivoxil in chronic respiratory tract infections by a double-blind method

A. Saito, Y. Hiraga, A. Watanabe, A. Saito, K. Shimada, H. Kobayashi, S. Odagiri, F. Miki, R. Soejima, K. Oizumi, K. Hara, M. Nakashima, Shimaru Sasaki, Hiroshi Fukuhara, Jun Inadome, Yoshikazu Kawakami, Etsuro Yamaguchi, Akira Saito, Ichiro Nakayama, Masumi TomizawaYohmei Hiraga, Mitsuhide Ohmichi, Masashi Tamura, Kazuki Konishi, Kazuo Obara, Kunio Shirato, Yasuo Tanno, Akira Watanabe, Kiyoshi Konno, Tsuneo Sayama, Satoru Shoji, Mitsunobu Honma, Hiroyuki Nakai, Yoshihiro Honda, Masataka Katsu, Michihiro Sakauti, Akira Ohishi, Atsushi Saito, Kohya Shiba, Osamu Sakai, Hiroichi Tanimoto, Kaoru Shimada, Yasuyuki Sano, Yasufumi Miyamoto, Hiroyuki Kobayashi, Shin Kawai, Susumu Sakayori, Izum Hayashi, Koichiro Kudo, Tadashi Horiuchi, Takashi Inamatsu, Masaru Koyama, Takeshi Mori, Koichiro Nakata, Tatsuo Nakatani, Harumi Shishido, Hideaki Nagai, Otohiko Kunii, Yoshio Uzuka, Jingoro Shimada, Seiji Hori, Takao Okubo, Hirotada Ikeda, Hiroo Yamakawa, Fumio Matsumoto, Takeo Imai, Shigeki Odagiri, Kaneo Suzuki, Hiroshi Takahashi, Ken Ichi Takahashi, Takashi Ogura, Eri Hagiwara, Masaaki Arakawa, Koichi Wada, Fumihide Iwate, Nobuki Aoki, Osamu Sekine, Yasutoshi Suzuki, Kaoru Shimokata, Toshiyuki Yamamoto, Kanzo Suzuki, Toru Matuura, Shigeru Shirakawa, Shin Ichi Kageyama, Kojiro Yasunaga, Seibun Yonezu, Yoshitaka Yamanaka, Fumio Miki, Masaru Nakagawa, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Rinzo Soejima, Yoshihito Niki, Niro Okirnoto, Michio Yamakido, Soichiro Hozawa, Hideto Yamakido, Takao Sasaki

    Research output: Contribution to journalArticlepeer-review

    4 Citations (Scopus)

    Abstract

    In a double-blind study, the efficacy and safety of the novel cephem antibiotic cefcapene pivoxil (CFPN-PI; 450 mg/day) was compared with cefteram pivoxil (CFTM-PI; 600 mg/day) in 171 patients with chronic respiratory tract infections. There was no significant difference between the clinical efficacy of the two drugs (80.2% for CFPN-PI versus 78.9% for CFTM-PI). There was no significant difference in the rate of elimination of the causative bacteria (60.5% for CFPN-PI versus 65.9% for CFTM-PI). Side-effects were observed in 6.0% of patients treated with CFPN-PI compared with 6.4% of patients treated with CFTM-PI. There were no significant differences in incidence of abnormal laboratory findings following treatment with the two drugs (13.9% for each), and none of the side-effects was severe. We conclude that CFPN-PI (450 mg/day) was as effective and as well tolerated as CFTM-PI (600 mg/day) in the treatment of chronic respiratory tract infections.

    Original languageEnglish
    Pages (from-to)590-607
    Number of pages18
    JournalJournal of International Medical Research
    Volume32
    Issue number6
    DOIs
    Publication statusPublished - 2004

    Keywords

    • Antibiotics
    • Cefcapene pivoxil
    • Cefteram pivoxil
    • Chronic respiratory tract infection
    • Double-blind study

    ASJC Scopus subject areas

    • Biochemistry
    • Cell Biology
    • Biochemistry, medical

    Fingerprint Dive into the research topics of 'Comparative clinical study of cefcapene pivoxil and cefteram pivoxil in chronic respiratory tract infections by a double-blind method'. Together they form a unique fingerprint.

    Cite this